Neuregulin-1 signalling and antipsychotic treatment
- 1.5k Downloads
Identifying the signalling pathways underlying the pathophysiology of schizophrenia is an essential step in the rational development of new antipsychotic drugs for this devastating disease. Evidence from genetic, transgenic and post-mortem studies have strongly supported neuregulin-1 (NRG1)–ErbB4 signalling as a schizophrenia susceptibility pathway. NRG1–ErbB4 signalling plays crucial roles in regulating neurodevelopment and neurotransmission, with implications for the pathophysiology of schizophrenia. Post-mortem studies have demonstrated altered NRG1–ErbB4 signalling in the brain of schizophrenia patients. Antipsychotic drugs have different effects on NRG1–ErbB4 signalling depending on treatment duration. Abnormal behaviours relevant to certain features of schizophrenia are displayed in NRG1/ErbB4 knockout mice or those with NRG1/ErbB4 over-expression, some of these abnormalities can be improved by antipsychotic treatment. NRG1–ErbB4 signalling has extensive interactions with the GABAergic, glutamatergic and dopaminergic neurotransmission systems that are involved in the pathophysiology of schizophrenia. These interactions provide a number of targets for the development of new antipsychotic drugs. Furthermore, the key interaction points between NRG1–ErbB4 signalling and other schizophrenia susceptibility genes may also potentially provide specific targets for new antipsychotic drugs. In general, identification of these targets in NRG1–ErbB4 signalling and interacting pathways will provide unique opportunities for the development of new generation antipsychotics with specific efficacy and fewer side effects.
KeywordsSchizophrenia Neuregulin-1 ErbB4 receptor Antipsychotic Glutamatergic GABA Dopaminergic Drug target
This study was supported by a University of Wollongong URC grant and an NHMRC project grant (APP1008473) to C. Deng, and the Schizophrenia Research Institute, Australia, utilising infrastructure funding from NSW Health. We would like to thank Dr Katrina Green for her critical reading of this manuscript.
Conflict of interest
The authors have no conflicts of interest to disclose.
- Bjarnadottir M, Misner DL, Haverfield-Gross S, Bruun S, Helgason VG, Stefansson H et al (2007) Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/− knock-outs compared with wild-type mice. J Neurosci 27:4519–4529PubMedCrossRefGoogle Scholar
- Correll CU (2010) From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. European Psychiatry 25. Supplement 2:S12–S21Google Scholar
- Fatemi SH, Folsom TD (2009): The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophrenia BulletinGoogle Scholar
- Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X et al (2010) A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 55:1907–1914PubMedCrossRefGoogle Scholar
- Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF et al (2011) Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 13:83–92PubMedCrossRefGoogle Scholar
- Mei L, Xiong W-C (2008) Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev 9:437–452Google Scholar
- Murray CJ, Lopez AD (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Harvard School of Public Health, Cambridge, MAGoogle Scholar
- O'Tuathaigh CMP, O'Connor A-M, O'Sullivan GJ, Lai D, Harvey R, Croke DT, Waddington JL (2008) Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry 32:462–466PubMedCrossRefGoogle Scholar
- van den Buuse M, Wischhof L, Lee RX, Martin S, Karl T (2009) Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol 29:1–11Google Scholar
- Woo T-UW, Walsh JP, Benes FM (2004) Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-d-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 61:649–657PubMedCrossRefGoogle Scholar
- Xu Z, Croslan DR, Harris AE, Ford GD, Ford BD (2006) Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke.[Erratum appears in J Cereb Blood Flow Metab. 2008 Sep;28(9):1643 Note: Dosage error in article text]. J Cereb Blood Flow Metab 26:527–535PubMedCrossRefGoogle Scholar
- Yokozeki T, Wakatsuki S, Hatsuzawa K, Black RA, Wada I, Sehara-Fujisawa A (2007) Meltrin β (ADAM19) mediates ectodomain shedding of Neuregulin β1 in the Golgi apparatus: fluorescence correlation spectroscopic observation of the dynamics of ectodomain shedding in living cells. Genes to Cells 12:329–343PubMedCrossRefGoogle Scholar
- Zhang H-X, Li W-Q, Zhang H-S, Zhang Y, Zhao J-P, Lv L-X, Yang G (2011) Expressional changes of neuregulin-1 gene mRNA in peripheral blood from schizophrenia patients. Chung Hua I Hsueh I Chuan Hsueh Tsa Chih 28:620–624Google Scholar